Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMTI NASDAQ:CYTK NASDAQ:ENDP NASDAQ:INVA NASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/ACYTKCytokinetics$37.01+1.1%$32.73$29.31▼$61.38$4.42B0.591.53 million shs960,448 shsENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsINVAInnoviva$18.77-1.5%$19.79$16.67▼$22.00$1.18B0.37705,522 shs764,766 shsKNSAKiniksa Pharmaceuticals International$28.09-3.0%$27.72$17.82▼$30.69$2.05B0.05555,944 shs355,269 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%CYTKCytokinetics0.00%+9.17%+11.48%-4.24%-32.62%ENDPEndo International0.00%0.00%0.00%0.00%0.00%INVAInnoviva0.00%-2.24%-12.29%+7.13%+11.86%KNSAKiniksa Pharmaceuticals International0.00%+0.84%+1.30%+45.47%+34.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMTIApplied Molecular TransportN/AN/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics3.9814 of 5 stars4.51.00.04.61.60.80.0ENDPEndo International0.2267 of 5 stars0.00.00.03.50.01.70.0INVAInnoviva4.1084 of 5 stars3.50.00.04.22.11.71.9KNSAKiniksa Pharmaceuticals International3.4039 of 5 stars3.54.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMTIApplied Molecular Transport 0.00N/AN/AN/ACYTKCytokinetics 2.93Moderate Buy$70.9291.63% UpsideENDPEndo International 0.00N/AN/AN/AINVAInnoviva 3.00Buy$40.50115.77% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$39.3340.03% UpsideCurrent Analyst Ratings BreakdownLatest ENDP, INVA, KNSA, AMTI, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/7/2025CYTKCytokineticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/2/2025CYTKCytokineticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.005/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMTIApplied Molecular TransportN/AN/AN/AN/A$1.56 per shareN/ACYTKCytokinetics$19.22M229.99N/AN/A($1.15) per share-32.18ENDPEndo International$2.99B0.00N/A0.06($13.60) per share0.00INVAInnoviva$369.84M3.19$3.43 per share5.48$11.03 per share1.70KNSAKiniksa Pharmaceuticals International$481.17M4.26N/AN/A$6.60 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMTIApplied Molecular Transport-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/ACYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)ENDPEndo International-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/AINVAInnoviva$23.39M-$1.01N/A12.11N/A-16.15%15.77%8.41%7/29/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A112.36N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)Latest ENDP, INVA, KNSA, AMTI, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025INVAInnoviva$0.43N/AN/AN/A$87.10 millionN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMTIApplied Molecular TransportN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AENDPEndo InternationalN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMTIApplied Molecular TransportN/A4.994.99CYTKCytokineticsN/A5.995.99ENDPEndo InternationalN/A1.861.62INVAInnoviva0.402.482.30KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMTIApplied Molecular Transport41.79%CYTKCytokineticsN/AENDPEndo International80.39%INVAInnoviva99.12%KNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipAMTIApplied Molecular Transport15.90%CYTKCytokinetics2.70%ENDPEndo International1.20%INVAInnoviva2.25%KNSAKiniksa Pharmaceuticals International53.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMTIApplied Molecular Transport1341.34 million34.76 millionOptionableCYTKCytokinetics250119.43 million116.20 millionOptionableENDPEndo International3,103235.14 million232.32 millionNo DataINVAInnoviva10062.78 million61.36 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableENDP, INVA, KNSA, AMTI, and CYTK HeadlinesRecent News About These CompaniesWells Fargo & Company Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) StockJuly 9, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)July 9, 2025 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded to "Buy" at Wall Street ZenJuly 7, 2025 | americanbankingnews.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street ZenJuly 6, 2025 | marketbeat.comKiniksa Pharmaceuticals: A 7.9 Score and Room for GrowthJuly 2, 2025 | msn.comKiniksa Pharmaceuticals: A 7.9 Score and Room for GrowthJuly 2, 2025 | msn.com5 Biotech Stocks to Buy in 2025 Amid Uncertain MacroenvironmentJuly 2, 2025 | zacks.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsJuly 2, 2025 | marketbeat.comPeregrine Capital Management LLC Has $6.87 Million Stock Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)July 1, 2025 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Lowered to "Hold" Rating by Wall Street ZenJune 28, 2025 | marketbeat.comAMI Asset Management Corp Acquires 26,010 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)June 26, 2025 | marketbeat.comKiniksa Pharmaceuticals International PLC - KNSA | Barron'sJune 24, 2025 | barrons.comKiniksa pharma COO Tessari sells $489k in sharesJune 19, 2025 | investing.comKiniksa pharma COO Tessari sells $489k in sharesJune 19, 2025 | investing.comEben Tessari Sells 17,300 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) StockJune 19, 2025 | insidertrades.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLCJune 19, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 17,300 Shares of StockJune 18, 2025 | marketbeat.comKiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing FastJune 16, 2025 | seekingalpha.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded at Wall Street ZenJune 14, 2025 | marketbeat.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 12, 2025 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $437,316.25 in StockJune 6, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENDP, INVA, KNSA, AMTI, and CYTK Company DescriptionsApplied Molecular Transport NASDAQ:AMTIApplied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.Cytokinetics NASDAQ:CYTK$37.01 +0.42 (+1.15%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$35.93 -1.08 (-2.92%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Endo International NASDAQ:ENDPEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.Innoviva NASDAQ:INVA$18.77 -0.29 (-1.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$17.86 -0.91 (-4.84%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.09 -0.86 (-2.97%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$28.24 +0.15 (+0.52%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Conagra at Rock Bottom: 7% Yield & Turnaround Poised Delta Air Lines Could Reach New Highs in 2025—And Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
